Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H21N3O4S |
| Molecular Weight | 351.421 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CCC=CC3)C(=O)N2[C@H]1C(O)=O
InChI
InChIKey=RPBAFSBGYDKNRG-NJBDSQKTSA-N
InChI=1S/C16H21N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-4,7,9-11,14H,5-6,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1
| Molecular Formula | C16H21N3O4S |
| Molecular Weight | 351.421 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Epicillin, a penicillin antibiotic, has never been approved in the USA, however, was studied for the treatment of childhood pneumonia, gonorrhea. Epicillin didn’t show any therapeutic advantages for parenteral treatment over ampicillin. By now, ampicillin remains the best-documented drug.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Where is the supporting evidence for treating mild to moderate chronic obstructive pulmonary disease exacerbations with antibiotics? A systematic review. | 2008-10-10 |
|
| Identification of penicillin allergenic determinants that bind IgE antibodies in the sera of subjects with penicillin allergy. | 1990-11 |
Patents
Sample Use Guides
oral dose of epicillin in the treatment of gonorrhoea: (a) 2 g epicillin plus 1 g probenecid, (b) 2 g epicillin alone, (c) 1 g epicillin, 1 g cephradine plus 1 g probenecid, and (d) 1 g epicillin and 1 g cephradine.
11 patients with cholelithiasis and choledocholithiasis: were administered i.v.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:54:30 GMT 2025
by
admin
on
Mon Mar 31 17:54:30 GMT 2025
|
| Record UNII |
3LU1L73C8Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QJ01CA07
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
||
|
NCI_THESAURUS |
C1500
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
||
|
WHO-ATC |
J01CA07
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
EPICILLIN
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
PRIMARY | |||
|
58974
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
PRIMARY | |||
|
2996
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
PRIMARY | |||
|
248-001-7
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
PRIMARY | |||
|
26774-90-3
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
PRIMARY | |||
|
C100212
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
PRIMARY | |||
|
SUB06563MIG
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
PRIMARY | |||
|
3LU1L73C8Y
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
PRIMARY | |||
|
100000080470
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
PRIMARY | |||
|
71392
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
PRIMARY | |||
|
DTXSID60181288
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
PRIMARY | |||
|
1025
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
PRIMARY | |||
|
DB13300
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
PRIMARY | |||
|
CHEMBL2104266
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
PRIMARY | |||
|
C80590
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
PRIMARY | |||
|
m4939
Created by
admin on Mon Mar 31 17:54:30 GMT 2025 , Edited by admin on Mon Mar 31 17:54:30 GMT 2025
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |